1374774-69-2 Usage
Uses
Used in Pharmaceutical Synthesis:
C12H11N3O2 is used as an intermediate in the synthesis of Naldemedine (N232550), a peripherally selective mu opioid receptor antagonist. C12H11N3O2 is particularly effective in the treatment of pain, as it selectively targets the peripheral opioid receptors, reducing the risk of central nervous system side effects such as respiratory depression and addiction.
Used in Pain Management:
In the pharmaceutical industry, C12H11N3O2 is used as a key component in the development of Naldemedine, a drug that targets peripheral opioid receptors to alleviate pain. This selective action minimizes the risk of central nervous system side effects, making it a valuable option for patients suffering from chronic pain.
Used in Drug Delivery Systems:
While the provided materials do not specifically mention the use of C12H11N3O2 in drug delivery systems, its role as an intermediate in the synthesis of Naldemedine suggests that it may also be involved in the development of novel drug delivery systems. These systems could potentially improve the bioavailability, delivery, and therapeutic outcomes of Naldemedine and other related compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 1374774-69-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,7,4,7,7 and 4 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1374774-69:
(9*1)+(8*3)+(7*7)+(6*4)+(5*7)+(4*7)+(3*4)+(2*6)+(1*9)=202
202 % 10 = 2
So 1374774-69-2 is a valid CAS Registry Number.
1374774-69-2Relevant academic research and scientific papers
CRYSTAL OF 6,7-UNSATURATED-7-CARBAMOYL MORPHINAN DERIVATIVE AND METHOD FOR PRODUCING THE SAME
-
Paragraph 0231-0234, (2013/09/12)
Stable crystalline forms of a compound represented by the formula (IA): an acid addition salt, and/or a solvate thereof are provided by the present invention. Said crystalline forms are extremely useful as materials for preparing medicines. Novel processes for preparing 6,7-unsaturated-7-carbamoyl morphinan derivatives are also provided by the present invention.
